Number of patient-reported asthma triggers predicts uncontrolled disease among specialist-treated patients with severe asthma

Ann Allergy Asthma Immunol. 2023 Jun;130(6):784-790.e5. doi: 10.1016/j.anai.2023.03.001. Epub 2023 Mar 10.

Abstract

Background: Patients with severe asthma (SA) experience a high disease burden, often precipitated by exposure to disease triggers.

Objective: To evaluate the prevalence and effects of patient-reported triggers on asthma disease burden in a cohort of subspecialist-treated patients with SA in the United States.

Methods: CHRONICLE is an observational study of adults with SA receiving biologics or maintenance systemic corticosteroids or whose disease is uncontrolled on high-dosage inhaled corticosteroids and additional controllers. Data were analyzed for patients enrolled between February 2018 and February 2021. This analysis evaluated patient-reported triggers from a 17-category survey and associations with multiple measures of disease burden.

Results: Among 2793 enrolled patients, 1434 (51%) completed the trigger questionnaire. The median trigger number per patient was 8 (interquartile range, 5-10). The most frequent triggers were weather or air changes, viral infections, seasonal allergies, perennial allergies, and exercise. Patients reporting more triggers experienced more poorly controlled disease, worse quality of life, and reduced work productivity. The annualized rates of exacerbations and asthma hospitalizations increased by 7% and 17%, respectively, for each additional trigger (both P < .001). For all measures, trigger number was a stronger predictor of disease burden than blood eosinophil count.

Conclusion: Among US specialist-treated patients with SA, asthma trigger number was positively and significantly associated with greater uncontrolled disease burden across multiple measures, which highlights the importance of understanding patient-reported triggers in SA.

Trial registration: ClinicalTrials.gov Identifier: NCT03373045.

Publication types

  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use
  • Adult
  • Anti-Asthmatic Agents* / therapeutic use
  • Asthma* / drug therapy
  • Asthma* / epidemiology
  • Humans
  • Hypersensitivity*
  • Patient Reported Outcome Measures
  • Quality of Life

Substances

  • Adrenal Cortex Hormones
  • Anti-Asthmatic Agents

Associated data

  • ClinicalTrials.gov/NCT03373045